Genmab — Marts 2021
-
1048 - Targeting BCL-2 and CD38 in models of acute myeloid leukemia reduces tumour burden https://www.abstractsonline.com/pp8/#!/9325/presentation/1980 "This data supports that combination treatment with Venetoclax and Daratumumab could have an important clinical application in the treatment of AML."
-
953 - Efficacy of amivantamab, a bispecific EGFR/MET antibody, correlates with EGFR expression and signaling in NSCLC models with wild-type EGFR https://www.abstractsonline.com/pp8/#!/9325/presentation/2464
-
Pæn salgsblok i 2035 på 6600 stk.
-
Slut: 2032
-
nåja - bedre end et spark i tænderne
-
så længe luk er over åbning skal det nok gå - men et decideret rebound skal vi nok kigge langt efter
-
så nogle nye data til at tænde raketten vil være dejligt - husk at vi inden for en måned får at vide om Tiso får priority review. GENs første eget produkt på markedet. En major milestone
-
Det er ikke Amivantamab og Epco det hele...
-
og for en gammel regnskabsdreng som mig, er Tiso det første program, der reelt skaber en direkte forbindelse mellem toplinien og de omkostninger, den driver
-
Jeg tænker også, at det er en kæmpemæssig milestone for Jan, at han rent faktisk har operations og ikke bare omkostninger
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind